


VII<sup>th</sup> Topical Workshop on  
Modern Aspects in Nuclear Structure

*The Many Facets of Nuclear Structure*

**BORMIO 3-8 February 2025**




# SPES Low Energy RIB for nuclear physics and applications




**Alberto Andrichetto – INFN Laboratori di Legnaro**

# Talk overview



- The RIB production
- The Low Energy Beam Line
- The first radioactive beam
- Isolpharm: Radioisotopes for medicine



# The RIB production





# RIB production area



# The Target Ion Source system

## The SPES Front-End:


### The SPES TIS unit:




# TIS Remote Handling

## Remote Handling Framework:


Design focused on TIS unit lifecycle -> Positioning in the FE, Irradiation, Storage -> **Ready for Commissioning**




# The Low Energy Beam Line




# Low Energy Experimental area





# 1- SPES Tape Station (STS) for beam diagnostic



- ➔ Monitoring RIB composition and intensity by  $\gamma$ -ray spectroscopy
  - 2 HPGe detector
  - Coincidence with beta counters
  - As a reference for SPES-MED experiment



## 2 - Beta decay station (INFN-Milano)





-> Study on the structure of excited states in atomic nuclei

- Gamma detection using 5 HPGe detector (Galileo like)
- Beta tagging by EJ212 plastic scintillator
- Second detection point for Conversion Electron Spectroscopy


By courtesy of Giovanna Benzoni

### 3 – ISOLPHARM Irradiation Station




-> Station for Radionuclide Deposition & Quality Control

- \* Beam Collection on secondary target
- \* Isotopes Detection
- \* Pellet Handling



# IRIS - Life cycle of the secondary target



# The first ISOL beam


(for Source Commissioning)

SPES Phase 2a - commissioning of the **ISOL machine** - Production of the first Radioactive Ion Beam at LNL




1st RIB @ LNL: 14/11/2024

# The SPES commissioning phases



# Experimental Layout



-> Detection point installed just out of the ISOL Source bunker

**Beam** (pre-operation phase) :

$E_{\text{proton}} = 40 \text{ MeV}$


$I_{\text{proton}} = 100 \text{ nA}$

**Detectors:**

- 2 LaBr Scintillator
- 2 HPGe
- 5 Beta counters EJ212



# Experimental settings



SPES SiC target (1600°C)

13 mm diameter 

proton beam

- 40 MeV
- 100 nA





SPES FEBIAD Ion Source


(30 KeV 1+ Ion Beam)





Wien Filter set for mass 28  
(a.m.u.)




mass 28 composition:  
 $^{28}\text{P}^{1+}$ ,  $^{28}\text{Al}^{1+}$  (radioactive)  
 $\text{CO}^{1+}$ ,  $\text{N}_2^{1+}$  (stable)



RIB characterization by  
beta-gamma spectroscopy



# Gamma in-beam spectrum



By Courtesy of A. Gottardo, A. Goasduff

# ISOLPHARM

*SPES exotic beams for medicine*

## 1. National collaboration

Broad, focused on **radio-pharmaceutical development**: synthesis, characterization and preclinical tests (*vitro/vivo*)

## 2. Innovative method

Innovative production @ SPES of several carrier free + high purity (medical) radionuclides ( $^{111}\text{Ag}$ ,  $^{89}\text{Sr}$ ,  $^{131}\text{I}$ ,  $^{153}\text{Sm}$ ...)

## 4. Activities & experiments

CSN5 (physics application):  
ISOLPHARM\_Ag,  
ISOLPHARM\_EIRA, ADMIRAL  
CSN3 (nuclear physics): SPES\_MED  
MUR: PRIN ISOLPHARM\_CORE

## 3. Facility at SPES

An irradiation station, using the SPES low energy beams, is planned in the SPES building

**Also... Scientific and training hub**

# The ISOLPHARM method

By the ISOL technique is possible to select and trap a SINGLE RADIO-ISOTOPE ->

CARRIER FREE RADIOISOTOPES




+ **high specific activity**  
+ **radionuclidic purity**



ISOLPHARM is a Irradiation Station at spes

ISOL  
PHARM



# ISOLPHARM: 11 Years of activity

INFN experiments



2014 - 2017



Interdisciplinary Study Group on production of medical radioisotopes at SPES



2018 - 2019



Simulations and feasibility evaluation of Ag as radiopharmaceutical precursor



2020 - 2022



First production of  $^{111}\text{Ag}$  in reactor and beginning of *in-vitro* and *in-vivo* testing



2023 - 2025





Providing new tools for preclinical trials on 3D scaffolds




2024 - 2025



Follows the technological aspect for the radionuclide production



# Collaboration infrastructures





# Radionuclides of interest: Main RIB available at SPES

|                               | Isotope           | Half-life     | In-target production [nuclide/s] | Time to collect 1 MBq [h] | Activity for 1 day collection at EOB [MBq] | Activity for 1 day collection 1 day after EOB [MBq] | Application Ready in the market                                                                                                                                         |
|-------------------------------|-------------------|---------------|----------------------------------|---------------------------|--------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Silicon carbide (SiC) target  | $^{24}\text{Na}$  | 15.0 h        | 7.8e7                            | 0.12                      | 126                                        | 42                                                  |   |
|                               | $^{28}\text{Mg}$  | 20.9 h        | 8.8e6                            | n/a                       | 0.27                                       | 0.12                                                |                                                                                      |
|                               | $^7\text{Be}$     | 53.2 d        | 9.5e10                           | 0.13                      | 183                                        | 181                                                 |                                                                                      |
| Titanium carbide (TiC) target | $^{43}\text{K}$   | 22.3 h        | 9.8e7                            | 0.09                      | 181                                        | 86                                                  |                                                                                      |
|                               | $^{51}\text{Cr}$  | 27.7 d        | 3.9e7                            | 6.9                       | 0.348                                      | 0.345                                               |                                                                                      |
|                               | $^{47}\text{Sc}$  | 3.35 d        | 1.1e11                           | 0.05                      | 473                                        | 385                                                 |                                                                                      |
| Uranium carbide (UCx) target  | $^{111}\text{Ag}$ | <b>7.45 d</b> | <b>4.9e8</b>                     | <b>0.11</b>               | <b>1635</b>                                | <b>1490</b>                                         |   |
|                               | $^{131}\text{I}$  | 8.03 d        | 4.6e10                           | 0.05                      | 2078                                       | 1906                                                |                                                                                    |
|                               | $^{153}\text{Sm}$ | 46.3 h        | 6.7e8                            | 0.06                      | 944                                        | 659                                                 |                                                                                    |
|                               | $^{89}\text{Sr}$  | 50.57 d       | 1.6e9                            | 0.28                      | 302                                        | 298                                                 |                                                                                    |

# Radiopharmaceutical radiolabeled with $^{111}\text{Ag}$

## Therapeutic isotopes



→ No radiopharmaceuticals radiolabeled with  $^{111}\text{Ag}$  in the market.

→ Silver-111 can be produced @ SPES with high purity & with high production rate

→ No Isobaric contamination in the secondary target (also with LASER off)!

→  $^{111}\text{Ag}$  exhibits possible 'theranostic' properties similar to  $^{177}\text{Lu}$  which was recently approved by FDA.

→  $^{111}\text{Ag}$  has dosimetric behavior equal to  $^{186}\text{Re}$ , which was recently studied in Phase II trials

## $^{111}\text{Ag}$ properties

- $\beta^-$  emitter (average energy 360 keV)
- Good half-life (7.45 days)
- Average tissue penetration (1.8 mm)
- Medium energy  $\gamma$  rays -> SPECT candidate




| 111 Isobaric chain | Half-Life $T_{1/2}$ | Decay     | Target Yield                     |
|--------------------|---------------------|-----------|----------------------------------|
| Cadmium-111        | Stable              |           | Low yield production             |
| Silver-111         | 7.45 days           | $\beta^-$ | Good yield production            |
| Palladium-111      | 23.4 min            | $\beta^-$ | Bad release, short $T_{1/2}$     |
| Rhodium-111        | 11 sec.             | $\beta^-$ | No release, very short $T_{1/2}$ |

# *In vivo* experiment with $^{111}\text{Ag}$ (april '24)


Routine production of Ag-111 at the LENA facilities, purification and quality control

1) 150 mg of  $^{110}\text{Pd}$   
irradiated in the TRIGA reactor



2)  $^{110}\text{Pd}$  vs.  $^{111}\text{Ag}$   
Separation at L.E.N.A.

$^{111}\text{Ag}$   $^{109}\text{Pd}$  contained  
inside cold  $^{110}\text{Pd}$  target





3) **88 MBq** of  $^{111}\text{Ag}$   
ship to CAPIR Lab

$^{111}\text{Ag}$



Biodistribution



In-vivo  
imaging



# Other experiments with $^{111}\text{Ag}$ performed in 2024


1. *In vitro* test - Cell survival  
@ UniPv (**WP4**)

20 MBq




2. Beta Ag detector test  
@ L.E.N.A. (**WP2**)

3 MBq



1. Gamma Ag detector test  
@ L.E.N.A. (**WP3**)

1,6 MBq






# Conclusions

# Low Energy RIBS at SPES: Future scenario

2025:  $^{24}\text{Na}$  from **SiC target** (commissioning LIS)

2026:  $^7\text{Be}$  from **SiC target** (low activity expected)

2027-28:  $^{51}\text{Cr}$  (low activity expected),  $^{43}\text{K}$  from **TiC target** +  $^{111}\text{Ag}$  +.... from **UC<sub>x</sub>**



Yield measurement the radionuclides-radiotracers & study for possible applications in:

- medicine -> ISOLPHARM



- environment



- industry.




# Activities with SPES radioisotopes at LNL

- ☒ In the Low Energy Experimental Room, it will be possible to start experiments with RIB for Nuclear physics and Medical applications

## \* SPES\_MED experiment:

Nuclear Yield measurements of RIB produced by a Carbide target (just started at CSN3)




After measurements, either:

- dispose of the radionuclide
- reuse it for applications ?



## \* ISOLPHARM – ADMIRAL experiment:

Radiobiology, Detector Technology and Nuclear Medicine study with  $^{111}\text{Ag}$  produced by TRIGA reactor



Opportunity to start test of Radiobiology with new radiotracers coming from SiC & TiC target



**Radiobiology** is a field of sciences that involves **study of the effects of ionizing radiation on living things**, in particular health effects of radiation.

# Collaboration network



Trento Institute for  
Fundamental Physics  
and Applications



Alberto Andrichetto Bormio 2025

# THANKS FOR YOUR ATTENTION!

The presented activities are the result of the work of the whole SPES-ISOL & ISOLPHARM teams

